Chemomab Therapeutics Ltd DRC (CMMB) — Cash Flow-to-Debt Ratio
Chemomab Therapeutics Ltd DRC (CMMB) has a Cash Flow-to-Debt Ratio of -7.59x as of December 2025, meaning its operating cash flow of $-11.22 Million could theoretically repay -8% of its total liabilities ($1.48 Million) in one year. See CMMB financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Chemomab Therapeutics Ltd DRC Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Chemomab Therapeutics Ltd DRC across 11 annual periods. For the full cash flow conversion analysis, see CMMB cash generation efficiency.
Annual Cash Flow-to-Debt Ratio for Chemomab Therapeutics Ltd DRC (2015–2025)
Year-by-year debt coverage analysis for Chemomab Therapeutics Ltd DRC. Check CMMB operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -7.59x | $-11.22 Million | $1.48 Million | ▼ -68.3% |
| 2024 | -4.51x | $-15.46 Million | $3.43 Million | ▲ +1.3% |
| 2023 | -4.57x | $-23.55 Million | $5.15 Million | ▼ -54.0% |
| 2022 | -2.97x | $-20.29 Million | $6.84 Million | ▲ +30.8% |
| 2021 | -4.29x | $-12.38 Million | $2.89 Million | ▲ +43.9% |
| 2020 | -7.65x | $-12.80 Million | $1.67 Million | ▼ -124.4% |
| 2019 | -3.41x | $-16.51 Million | $4.85 Million | ▲ +29.0% |
| 2018 | -4.80x | $-14.18 Million | $2.96 Million | ▼ -50.7% |
| 2017 | -3.18x | $-8.58 Million | $2.70 Million | ▼ -100.8% |
| 2016 | -1.59x | $-3.74 Million | $2.36 Million | ▲ +70.6% |
| 2015 | -5.38x | $-7.38 Million | $1.37 Million | — |